Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Socie...(e Private Securities Litigation Reform A...)

Date:11/2/2009

e Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those
'/>"/>

SOURCE Sanofi Pasteur Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
2. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
3. Sanofi-aventis Announces Second Quarter 2009 Results
4. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
5. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
6. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
7. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
8. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
11. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster